LONDON (AP) — The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing ...

The European Medicines Agency has recommended the approval of lenacapavir, a new bi-annual injectable drug aimed at ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

Gilead receives positive CHMP opinions under accelerated review from EMA for twice-yearly lenacapavir for HIV prevention: Foster City, California Saturday, July 26, 2025, 13:00 Hr ...

Parents with children insured by Medicaid fear changes to the government program mean vaccines will no longer be covered.

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Gilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for ...

DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...